Koker, Mirjam

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J., Fischer, F., Frommolt, P., et al. (2009) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 504

HMGB2 Loss upon Senescence Entry Disrupts Genomic Organization and Induces CTCF Clustering across Cell Types

Zirkel, A., Nikolic, M., Sofiadis, K., Mallm, J.-P., Brackley, C. A., Gothe, H., Drechsel, O., Becker, C., Altmüller, J., Josipovic, N., et al. (2018) · Molecular Cell

Genomics and Chromatin DynamicsTelomeres, Telomerase, and Senescence

Cited by 226

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.

Sos, M. L., Rode, H. B., Heynck, S., Peifer, M., Fischer, F., Klüter, S., Pawar, V. G., Reuter, C., Heuckmann, J. M., Weiss, J., et al. (2010) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 220